# Anthem BioSciences (ANTHEM) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/anthem

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹915
- Change: +0.16%
- As of: 2026-11-06
- 1D return: +0.16%
- 5D return: +10.40%
- 1M return: +4.87%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

As of the close on 5 November 2026, ANTHEM trades at ₹911.85, reflecting a +2.7% daily gain and a strong upward gap. The stock is positioned near the upper end of its recent trading ranges (+96.5% in the 20-day range, +83.5% in the 252-day range), indicating significant relative strength. Price action remains above all key moving averages (EMA/SMA 20/50/200) and the Supertrend across daily, weekly, and monthly timeframes, confirming a structural uptrend.

Trend conviction varies by horizon: the weekly (ADX 32.04) and monthly (ADX 29.94) trends are established with bullish directional indicators (+DI > -DI), while the daily trend (ADX 22.04) is developing. Recent anomalies include a high-severity upward gap on 5 November and volume-backed price moves on 4 November, suggesting active participation. Risk metrics show an annualized volatility of +30.7% and a current drawdown of -4.8% from the available high. Immediate resistance lies at ₹922.50 (+1.17%), with support at ₹905.40 (-0.71%). A sustained hold above the 20-day EMA and Supertrend would reinforce the bullish structure, while a break below ₹905.40 could signal short-term consolidation.

- Price Structure: Trading at ₹911.85, well above all major moving averages and Supertrend lines across daily, weekly, and monthly charts.
- Trend Strength: Weekly (ADX 32.04) and monthly (ADX 29.94) trends are established; daily trend (ADX 22.04) is developing but supported by recent high-volume gains.
- Key Levels: Nearest resistance at ₹922.50 (+1.17%); immediate support at ₹905.40 (-0.71%).
- Risk & Volatility: Annualized volatility stands at +30.7%; current drawdown is -4.8% from the period high.

- Morning Star
- Bullish Engulfing Reversal
- Doji
- Inside Bar

### News Context

On November 6, 2026, Anthem Biosciences Limited was identified as a top stock recommendation by Hitesh Rathi, Technical Analyst at Angel One. The selection was based on specific technical indicators, including W-pattern breakouts, bullish bear traps, and support confluences, which the analyst cited as signals for continued upward momentum. This report represents third-party technical analysis rather than a corporate announcement or fundamental business development from the company itself.

- Anthem Biosciences Limited was listed among top stock recommendations for November 6, 2026, by Angel One.
- Hitesh Rathi, Technical Analyst at Angel One, attributed the recommendation to technical patterns: W-pattern breakouts, bullish bear traps, and support confluences.
- The view reflects external technical analysis; no new corporate filings, operational updates, or financial results were reported in the supplied evidence.

- [Top stocks to buy today: Stock market recommendations for November 6, 2026 - check list](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-november-06-2026-apl-apollo-tubes-lenskart-anthem-biosciences-limited-stocks-to-buy-today/articleshow/135590744.cms)

### What Changed

Anthem Biosciences Limited (NSE: ANTHEM) has seen a material shift in market sentiment and technical positioning as of early November 2026. On November 5, 2026, the stock price rose to ₹911.85, up from ₹888.30 on the previous observation date, reflecting a positive technical breakout. This upward momentum was reinforced by analyst recommendations from Angel One on November 6, 2026, which cited W-pattern breakouts and bullish bear traps as indicators for continued strength.

Corporate activity also updated during this period. On November 5, 2026, the company filed with the NSE to make available the audio recording of its earnings call held on November 4, 2026. The call covered unaudited financial results for the quarter and half-year ended September 30, 2026. While the specific financial figures from the call are not detailed in the current evidence, the availability of the recording signals transparency regarding recent operational performance.

The combination of technical buy signals and fresh investor communication marks a change from prior static periods. Investors should monitor whether the technical momentum sustains following the release of the earnings call details.

- Price Action: Stock closed at ₹911.85 on November 5, 2026, up from ₹888.30, indicating short-term upward momentum.
- Analyst Sentiment: Angel One included Anthem Biosciences in its top stock recommendations for November 6, 2026, citing technical breakouts.
- Corporate Filing: Audio recording of the Q2/H1 FY2026-27 earnings call (held Nov 4, 2026) was made available via NSE filing on November 5, 2026.

- [Top stocks to buy today: Stock market recommendations for November 6, 2026 - check list](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-november-06-2026-apl-apollo-tubes-lenskart-anthem-biosciences-limited-stocks-to-buy-today/articleshow/135590744.cms)
- [Anthem Biosciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05112026160919_Investor_Call_Audio_Recoding_Q2.pdf)

### Official Filings

Anthem Biosciences Limited has released its unaudited financial results for the quarter and half-year ended September 30, 2026 (Q2 & H1 FY27), approved by the Board on November 3, 2026. The company reported consolidated revenue from operations of ₹5,940 million for Q2FY27, marking a 7.9% year-on-year increase, while H1FY27 revenue stood at ₹10,123 million, down 7.2% year-on-year. Profit After Tax (PAT) improved significantly in Q2FY27 to ₹2,115 million (up 21.9% YoY), with an EBITDA margin expansion to 44.5%-50.6% depending on the specific reporting line, driven by cost efficiencies and forex gains. The company maintains a strong net cash position of ₹15,380 million as of September 30, 2026. Additionally, 143,285 equity shares were allotted under the Employee Stock Option Plan 2024 during the quarter. An earnings call was held on November 4, 2026, and the company will participate in the JM Financial India Xchange 2026 in Mumbai from November 16-18, 2026.

- Q2FY27 Revenue: ₹5,940 Mn (+7.9% YoY); H1FY27 Revenue: ₹10,123 Mn (-7.2% YoY)
- Q2FY27 PAT: ₹2,115 Mn (+21.9% YoY); Net Cash Position: ₹15,380 Mn as of Sep 30, 2026
- ESOP Allotment: 143,285 equity shares issued under ESOP 2024 during Q2FY27
- Upcoming Engagement: Physical investor meetings scheduled for Nov 16-18, 2026, in Mumbai

- [ANTHEM BIOSCIENCES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_25167_WebXMLFile_20261105_132808620.xml)
- [Anthem Biosciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05112026133027_Q2FY27_Investor_Meet_Intimation_Signed.pdf)
- [Anthem Biosciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05112026160919_Investor_Call_Audio_Recoding_Q2.pdf)
- [Anthem Biosciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_04112026123555_Newspaper_Publication_Q2FY27.pdf)
- [Anthem Biosciences Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026175122_Outcome_of_BM_Q2FY27__1_.pdf)
- [Anthem Biosciences Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026180049_Investors_Presentation.pdf)
- [Anthem Biosciences Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press Release on the Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2026 ". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026175741_Press_Release_Q2FY27.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752341_03112026102736_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752342_03112026102741_WEB.xml)
- [ANTHEM BIOSCIENCES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_25167_WebXMLFile_20261030_183344241.xml)

### Fundamentals

Anthem Biosciences demonstrates a robust operational turnaround in Q2 FY2026-27, marked by strong sequential growth and significant balance-sheet deleveraging. Revenue from operations rose to ₹594 crore from ₹418 crore in Q1, driving Profit Before Tax (PBT) to ₹296 crore and Net Profit to ₹211 crore, compared to ₹120 crore in the prior quarter. This profitability surge is supported by a sharp reduction in finance costs, which fell from ₹88.7 lakh to ₹3.31 crore, reflecting a broader trend of debt reduction where borrowings declined to ₹40 crore as of September 2026.

Earnings quality has improved markedly, with Cash Flow from Operations (CFO) reaching ₹844 crore for the year ended March 2026, converting at 126% of operating profit. Working capital efficiency also shows structural improvement, with the Cash Conversion Cycle compressing significantly to 124 days by March 2026, driven primarily by a drop in Inventory Days to 56. While TTM sales show a slight contraction (-1%), the underlying momentum is evident in the 26% YoY sales growth recorded in March 2026 and consistent quarterly expansion. The company’s asset base expanded to ₹3,686 crore, with non-current assets rising to ₹1,805 crore, indicating continued investment in fixed capacity alongside reduced current liabilities.

The most critical next checkpoint is monitoring whether this high level of cash generation and margin expansion sustains as the company integrates its growing fixed-asset base into revenue streams, particularly given the recent dip in TTM top-line growth.

- Q2 FY2026-27 Net Profit surged to ₹211 crore (up from ₹120 crore in Q1), with EPS rising to ₹3.75 per share on revenue of ₹594 crore.
- Finance costs dropped sharply to ₹3.31 crore in Q2, contributing to borrowings falling to ₹40 crore by September 2026.
- Cash conversion strengthened significantly: CFO reached ₹844 crore (FY26) with a 126% conversion rate, while the Cash Conversion Cycle compressed to 124 days.
- TTM sales growth is -1%, contrasting with 26% YoY growth in March 2026; investors should watch if top-line momentum stabilizes.

### Bull Case

Anthem Biosciences presents a conditional upside case anchored in multi-timeframe technical strength and recent momentum. As of November 5, 2026, the stock closed at ₹911.85, reflecting a robust year-to-date return of +42.9% and a one-year gain of +29.8%. The weekly trend is explicitly bullish, with the Supertrend direction signaling upward momentum and positive slope indicators for both the 20-period (17.98) and 50-period (15.95) simple moving averages. This structural alignment suggests that despite a current short-term drawdown of -4.8%, the broader intermediate-term trajectory remains intact. Additionally, analyst commentary from November 6, 2026, highlights technical patterns such as W-pattern breakouts and bullish bear traps, reinforcing the view of continued upward potential if price action holds above key support levels like ₹905.4.

- Multi-timeframe bullish structure: Weekly and monthly Supertrends are bullish, with strong positive slopes on weekly SMAs (SMA_20_slope_5: 17.98; SMA_50_slope_5: 15.95).
- Strong historical momentum: Year-to-date return stands at +42.9%, with a 1-month return of +7.0% and 1-year return of +29.8% as of November 5, 2026.
- Recent technical signals: Analyst recommendations cite W-pattern breakouts and bullish bear traps as drivers for continued upward momentum.
- Key support proximity: Immediate support lies at ₹905.4 (0.71% below), providing a narrow buffer to monitor for trend continuation.

- [Top stocks to buy today: Stock market recommendations for November 6, 2026 - check list](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-november-06-2026-apl-apollo-tubes-lenskart-anthem-biosciences-limited-stocks-to-buy-today/articleshow/135590744.cms)
- [ANTHEM BIOSCIENCES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_25167_WebXMLFile_20261105_132808620.xml)
- [Anthem Biosciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05112026133027_Q2FY27_Investor_Meet_Intimation_Signed.pdf)
- [Anthem Biosciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05112026160919_Investor_Call_Audio_Recoding_Q2.pdf)
- [Anthem Biosciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_04112026123555_Newspaper_Publication_Q2FY27.pdf)
- [Anthem Biosciences Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026175122_Outcome_of_BM_Q2FY27__1_.pdf)
- [Anthem Biosciences Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026180049_Investors_Presentation.pdf)
- [Anthem Biosciences Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press Release on the Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2026 ". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026175741_Press_Release_Q2FY27.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752341_03112026102736_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752342_03112026102741_WEB.xml)

### FAQs

**What financial results did Anthem Biosciences report for the half-year ended September 30, 2026?**

The Board approved unaudited consolidated results on November 3, 2026. For the half-year, revenue from operations was ₹10,122.50 million with a profit after tax of ₹3,314.04 million. Statutory auditor S.R. Batliboi & Associates LLP issued a review report stating nothing came to their attention to suggest material misstatements in the Ind AS-compliant figures.

**How has the stock performed over key timeframes as of early November 2026?**

As of November 5, 2026, the stock closed at ₹911.85. Period returns include +42.9% year-to-date, +29.8% over one year, and +19.7% over six months. The stock has experienced a maximum drawdown of -31.5% historically, with an annualized volatility of +30.7%.

**What upcoming events allow investors to engage directly with management?**

Anthem Biosciences will participate in the JM Financial India Xchange 2026 in Mumbai from November 16 to November 18, 2026. The company confirmed it does not propose to share unpublished price sensitive information during these group and one-on-one physical meetings.

**What are the immediate technical support and resistance levels for the stock?**

Based on daily trends as of November 5, 2026, the nearest support level is ₹905.40 (0.71% below current price), followed by ₹872.90. Resistance levels are located at ₹922.50 (1.17% above) and ₹942.60 (3.37% above). Technical indicators such as the Supertrend remain bullish on both daily and monthly timeframes.

- [Top stocks to buy today: Stock market recommendations for November 6, 2026 - check list](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-november-06-2026-apl-apollo-tubes-lenskart-anthem-biosciences-limited-stocks-to-buy-today/articleshow/135590744.cms)
- [ANTHEM BIOSCIENCES LIMITED has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_25167_WebXMLFile_20261105_132808620.xml)
- [Anthem Biosciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05112026133027_Q2FY27_Investor_Meet_Intimation_Signed.pdf)
- [Anthem Biosciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05112026160919_Investor_Call_Audio_Recoding_Q2.pdf)
- [Anthem Biosciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_04112026123555_Newspaper_Publication_Q2FY27.pdf)
- [Anthem Biosciences Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026175122_Outcome_of_BM_Q2FY27__1_.pdf)
- [Anthem Biosciences Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026180049_Investors_Presentation.pdf)
- [Anthem Biosciences Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press Release on the Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2026 ". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026175741_Press_Release_Q2FY27.pdf)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752341_03112026102736_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752342_03112026102741_WEB.xml)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹905.02
- Risk regime: Price Risk Currently Contained

### Support levels
- 763.05
- 747.471875
- 734.075

### Resistance levels
- 942.6
- 977.55
- 924.9833333333336

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.16% |
| return_10 | +12.57% |
| return_1m | +2.77% |
| return_1y | +31.35% |
| return_20 | +4.87% |
| return_3m | +10.82% |
| return_5 | +10.40% |
| return_6m | +19.02% |
| return_since_start | +25.28% |
| return_ytd | +43.39% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -31.47% |
| annualized_volatility | +30.67% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Anthem Biosciences Q2 FY2026-27: PBT more than doubled sequentially

For the quarter ended 30 September 2026, revenue from operations rose 42% quarter on quarter (QoQ) to ₹594 crore, while profit before tax (PBT) increased 105% to ₹296 crore. Year on year (YoY), revenue grew 8%, PBT rose 29% and profit for the period advanced 22% to ₹211 crore.

## Revenue and income rebound

Total income was ₹653 crore, up 47% from ₹443 crore in Q1 FY2026-27 and 9% from ₹598 crore in Q2 FY2025-26. It comprised ₹594 crore of revenue from operations and ₹59 crore of other income.

Revenue from operations recovered from ₹418 crore in Q1 FY2026-27, though it remained below the ₹611 crore reported in Q4 FY2025-26. It was higher than the ₹423 crore recorded in Q3 FY2025-26.

## Profit growth outpaces revenue

PBT rose to ₹296 crore from ₹145 crore in Q1 FY2026-27 and was 29% above the ₹230 crore reported in Q2 FY2025-26. Total expenses increased 19% QoQ to ₹357 crore, less than the 42% increase in revenue from operations. Profit before exceptional items and tax was also ₹296 crore.

Tax expense was ₹84.9 crore, compared with ₹24.6 crore in Q1 FY2026-27. Profit for the period therefore rose 76% QoQ to ₹211 crore and was up 22% YoY. Diluted earnings per share was ₹3.72, versus ₹2.11 in Q1; trailing 12-month EPS was ₹10.91.

## Expense composition

Q2 expenses included ₹201 crore for materials consumed, ₹81 crore in employee benefits and ₹31 crore of depreciation and amortisation. Changes in inventories reduced expenses by ₹16 crore. Finance costs were ₹3.3 crore, up from ₹0.9 crore in Q1 FY2026-27.

## Cash flow and balance sheet

Operating cash flow was ₹318 crore. Investing activities used ₹207 crore, leaving free cash flow of ₹111 crore; financing activities used a further ₹108 crore.

Cash and cash equivalents stood at ₹20 crore on 30 September 2026, down from ₹273 crore on 31 March 2026 and ₹504 crore on 30 September 2025. The company also held current investments of ₹685 crore and noncurrent investments of ₹576 crore at quarter-end.

Total assets were ₹3,686 crore at 30 September 2026, compared with ₹3,429 crore at 31 March 2026. Equity rose to ₹3,281 crore from ₹3,043 crore, including other equity of ₹3,168 crore. Borrowings comprised ₹19.7 crore of noncurrent and ₹19.0 crore of current borrowings.

## Key Takeaway

The quarter combined a strong sequential revenue recovery with PBT more than doubling and positive YoY growth in revenue, PBT and profit. Operating cash flow exceeded investing outflows, but cash and cash equivalents fell to ₹20 crore at quarter-end, alongside substantial current and noncurrent investment balances.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q2
- As of: 2026-09-30
- Promoter holding: +71.40%
- FII holding: +3.79%
- DII holding: +12.10%
- Mutual fund holding: +9.25%
- Retail holding: +1.83%
- Promoter pledged: +0.00%

### Major reported shareholders

- AJAY BHARDWAJ — +42.39%
- ISHAAN BHARDWAJ — +10.12%
- GANESH SAMBASIVAM — +8.10%
- K C RAVINDRA — +7.75%
- PORTSMOUTH TECHNOLOGIES LLC — +2.73%
- MALAY JIBAN BARUA — +2.26%
- RUPESH NARHARRAO KINEKAR — +2.26%
- SATISH S SHARMA — +2.26%
- HDFC MUTUAL FUND - HDFC BUSINESS CYCLE FUND — +1.90%
- SBI MNC FUND — +1.75%

## Official filings

- 2026-11-06 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_06112026161829_Earnings_Call_Transcript_Signed.pdf)
- 2026-11-06 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_25167_WebXMLFile_20261106_174937750.xml)
- 2026-11-05 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_25167_WebXMLFile_20261105_132808620.xml)
- 2026-11-05 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05112026133027_Q2FY27_Investor_Meet_Intimation_Signed.pdf)
- 2026-11-05 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_05112026160919_Investor_Call_Audio_Recoding_Q2.pdf)
- 2026-11-04 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_04112026123555_Newspaper_Publication_Q2FY27.pdf)
- 2026-11-03 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026175122_Outcome_of_BM_Q2FY27__1_.pdf)
- 2026-11-03 — Earnings Presentation: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026180049_Investors_Presentation.pdf)
- 2026-11-03 — Press Release: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_03112026175741_Press_Release_Q2FY27.pdf)
- 2026-11-03 — Financial Results Filing: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752341_03112026102736_WEB.xml)
- 2026-11-03 — Financial Results Filing: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1752342_03112026102741_WEB.xml)
- 2026-10-30 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_25167_WebXMLFile_20261030_183344241.xml)
- 2026-10-30 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_30102026184221_Investor_Call_Intimation_Q2_Signed.pdf)
- 2026-10-28 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_25167_WebXMLFile_20261028_124940989.xml)
- 2026-10-28 — Board Meeting Notice: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_25167_WebXMLFile_20261028_124940989.xml)
- 2026-10-28 — Board Meeting Notice: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_28102026130506_BM_Intimation_Q2Signed.pdf)
- 2026-10-13 — Shareholding Disclosure: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1736823_13102026025758_WEB.xml)
- 2026-09-25 — Shareholding Disclosure: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1717456_24082026064738_WEB.xml)
- 2026-09-24 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_25167_WebXMLFile_20260924_193819137.xml)
- 2026-09-24 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_24092026194210_Trading_Window_Closure_Signed.pdf)
- 2026-09-23 — Shareholding Disclosure: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1718773_28082026112949_WEB.xml)
- 2026-09-21 — Financial Results Filing: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1726102_21092026064909_WEB.xml)
- 2026-09-08 — Generic Announcement: Anthem Biosciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_08092026221841_IntimationUpsideSharingSigned.pdf)
- 2026-07-27 — Official Filing: Anthem Biosciences Limited reported Q1 FY27 consolidated revenues of Rs. 418 crores, with CRDMO contributing Rs. 341 crores and Specialty Ingredients Rs. 78 crores. EBITDA was Rs. 176 crores (39.6% margin), and Profit After Tax was Rs. 120 crores (27.1% margin). The company noted timing shifts in customer deliveries, with underlying demand remaining strong and a higher concentration of deliveries expected in the latter half of the year. The net cash position as of June 30, 2026, was Rs. 1,720 crores. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_27072026105731_Earnings_Call_Transcript_Q1_Signed.pdf)
- 2026-07-24 — Generic Announcement: Anthem Biosciences Limited held its 20th Annual General Meeting on July 22, 2026, where all 8 resolutions presented were passed with the requisite majority. These resolutions included the adoption of financial statements for the year ended March 31, 2026, declaration of dividend, re-appointment of a director, appointment of statutory auditors, continuation of an independent director, and approval of commission payable to independent directors, remuneration to related parties, and an upside sharing arrangement with Viridity Tone LLP. — [Official attachment](https://nsearchives.nseindia.com/corporate/COMPLIANCE_ABL1_24072026155625_Voting_Results_Intimation_With_Annexure_numbers.pdf)

## News and market events

- 2026-11-06 — Times of India: **Top stocks to buy today: Stock market recommendations for November 6, 2026 - check list** — Hitesh Rathi, Technical Analyst at Angel One, identified APL Apollo Tubes, Lenskart, and Anthem Biosciences Limited as top stock recommendations for November 6, 2026. The analysis cites technical indicators such as W-pattern breakouts, bullish bear traps, and support confluences to suggest continued upward momentum for these equities. — [Source](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-november-06-2026-apl-apollo-tubes-lenskart-anthem-biosciences-limited-stocks-to-buy-today/articleshow/135590744.cms)
- 2026-09-11 — Mint: **Raja Venkatraman recommends three stocks for 11 September** — Market expert Raja Venkatraman shares his top stock picks for 11 September. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-11-september-11789058673473.html)
- 2026-09-03 — Mint: **Stock market today: Gift Nifty hints a positive start; eight day trading stocks to buy on Thursday, 3 September** — Indian stock market indices are expected to open higher, following positive global cues. However, previous sessions saw declines in the Sensex and Nifty 50. Global uncertainties related to the US-Iran conflict continue to weigh on market sentiment. — [Source](https://www.livemint.com/market/stock-market-news/stock-market-today-gift-nifty-hints-a-positive-start-eight-day-trading-stocks-to-buy-on-thursday-3-september-11788400588885.html)
- 2026-09-01 — Economic Times: **Anthem Biosciences Share Price Today, Anthem Biosciences Stock Price Live NSE/BSE Updates | The Economic Times** — Anthem Biosciences Share Price Today - Get live NSE/BSE quotes of Anthem Biosciences with latest news, headlines and quick analysis. View forecasts, quarterly results, dividend details, balance sheet & more. — [Source](https://economictimes.indiatimes.com/anthem-biosciences-ltd/stocks/companyid-2248725.cms)
- 2026-08-27 — MONEYCONTROL: **Goldman Sachs-backed CRDMO Aragen Life Sciences files IPO papers to raise Rs 800 crore fresh capital** — Aragen Life Sciences IPO size,Aragen Life Sciences IPO DRHP,Aragen Life Sciences IPO news,Aragen Life Sciences IPO details,Goldman Sachs — [Source](https://www.moneycontrol.com/news/business/ipo/goldman-sachs-backed-crdmo-aragen-life-sciences-files-ipo-papers-to-raise-rs-800-crore-fresh-capital-14017035.html)
- 2026-08-27 — Mint: **Raja Venkatraman recommends three stocks for 27 August** — Market expert Raja Venkatraman shares his top stock picks for 27 August. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-27-august-11787757519206.html)
- 2026-08-27 — Mint: **Stock recommendations for 27 August from MarketSmith India** — MarketSmith India reveals its top stock recommendations for today, 27 August. Get expert insights into the best-performing stocks to guide your investment decisions. — [Source](https://www.livemint.com/market/stock-market-news/stock-recommendations-27-august-marketsmith-india-11787761968102.html)
- 2026-08-21 — CNBC-TV18: **Stocks To Buy: Analysts have a consensus bullish call, Jefferies sees 20% upside** — Anthem Biosciences is a high-growth Indian contract research, development and manufacturing organisation (CRDMO) with industry-leading manufacturing capabilities and a technocrat-led management team. — [Source](https://www.cnbctv18.com/market/anthem-biosciences-share-price-jefferies-says-buy-target-upside-returns-revenue-profit-cagr-19974283.htm)
- 2026-08-21 — Economic Times: **Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target** — Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is bullish on the companys integrated CRDMO model, strong return ratios and growth prospects, forecasting 18% revenue CAGR through FY29. Key triggers include new commercial molecules and biosimilar launches, while customer concentration and high capex remain key risks. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/jefferies-initiates-coverage-on-anthem-biosciences-with-a-rs-1050-target/articleshow/133393891.cms)
- 2026-08-03 — MONEYCONTROL: **Trade Spotlight: How should you trade Hero MotoCorp, Anant Raj, Anthem Biosciences, KEI Industries, Escorts, BLS E-Services, and others on August 3?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,BLS E-Services,Hero MotoCorp,Jio Financial Services,Anant Raj,Anthem Biosciences,Blue Jet Healthcare,Shipping Corporation of India,KEI Industries,Escorts Kubota — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-hero-motocorp-anant-raj-anthem-biosciences-kei-industries-escorts-bls-e-services-and-others-on-august-3-13991407.html)
- 2026-07-22 — The Hindu: **Q1 Results LIVE: Nestle PAT up 48% y-o-y, Adani Green, Adani Power, Eternal, Dr Reddy's Lab, NTPC Green, BPCL, HPCL, IndusInd Bank to announce Q1 results today** — Q1 Results Today, 22nd July 2026: Follow our Q1 live updates here — [Source](https://www.thehindubusinessline.com/markets/fy27-q1-results-today-live-updates-adani-green-adani-power-ntpc-nestle-eternal-bpcl-hpcl-indusind-bank-dr-reddys-bajaj-auto-tvs-motor-adani-energy-atgl-mastek-sagility-july-22-2026/article71248906.ece)
- 2026-07-22 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty falls below 24,000 mark as market extends losses** — Sensex Today | Stock Market LIVE Updates: The markets are under immense pressure, with the Nifty index falling over 150 points, slumping towards 24,000. The Nifty Bank is down over 500 points, slumping towards 57,300. IndiGo, Cipla and and SBI are the top laggards. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-crude-bandhan-drl-adani-nestle-hpcl-eternal-bpcl-share-price-liveblog-19950949.htm)
- 2026-07-22 — CNBC-TV18: **Anthem Biosciences Q1 Results: Shares fall over 7% as delayed deliveries drag earnings** — Anthem Bio's Chairman, Managing Director and CEO Ajay Bhardwaj attributed the softer performance to the timing of customer deliveries rather than a slowdown in demand. — [Source](https://www.cnbctv18.com/market/anthem-biosciences-share-price-fall-q1-result-reaction-delayed-deliveries-revenue-profit-margins-outlook-cash-returns-19951098.htm)
- 2026-07-21 — FREEPRESSJOURNAL.IN: **Anthem Biosciences Reports Q1 Profit At ₹119.94 Crore, Revenue From Operations Down 31.54%** — Anthem Biosciences Limited reported a consolidated net profit of ₹119.94 crore for the quarter ended 30 June 2026. The company — [Source](https://www.freepressjournal.in/business/anthem-biosciences-reports-q1-profit-at-11994-crore-revenue-from-operations-down-3154)
- 2026-07-21 — Mint: **Raja Venkatraman recommends three stocks for 21 July** — Market expert Raja Venkatraman shares his top stock picks for 21 July. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-21-july-sensex-nifty-11784561114172.html)

## Business profile

**Strategic vision:** Health benefits company offering a wide range of insurance products and services.

### Business segments
- **Medical Plans:** Offers employer-sponsored, individual, and government-funded plans including Medicaid and Medicare.
- **Supplemental Benefits:** Provides dental, vision, group life, and disability insurance.
- **Pharmacy Benefits Management:** Manages pharmacy benefits through its subsidiary, IngenioRx.

### Competitive strengths
- Operates under multiple brand names, including Blue Cross Blue Shield in many states.
- Commitment to a whole health approach to improve health outcomes.
- Focus on innovation to drive progress and solutions in healthcare.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Aster DM Quality Care Limited (Healthcare)](https://faxioms.com/stocks/asterdm) — -1.03%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/anthem
Markdown representation: https://faxioms.com/stocks/anthem?render=md